Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,829

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

Open access
Wilhelm, Scott, Carter, Christopher, Lynch, Mark, Lowinger, Timothy, Dumas, Jacques, Smith, Roger A., Schwartz, Brian, Simantov, Ronit, Kelley, Susan·2006·Nature Reviews Drug Discovery

Abstract

In December 2005, sorafenib became the first new treatment to be approved for advanced renal cancer in more than a decade. Wilhelm and colleagues provide the history of this drug, which inhibits several kinases involved in tumour signalling and angiogenesis. Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) — from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 — was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd2130

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Research works printed but not linked: 27

  1. Niman, H. L. Antisera to a synthetic peptide of the sis viral oncogene product recognize human platelet-derived growth factor. Nature 307, 180–183 (1984). · doi:10.1038/307180a0
  2. McPhillips, F. et al. Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer. Br. J. Cancer 85, 1753–1758 (2001). · doi:10.1054/bjoc.2001.2139
  3. Riedl, B. et al. Potent Raf kinase inhibitors from the diphenylurea class: structure activity relationships. Clin. Cancer Res. 20, 83a (2001).
  4. Smith, R. A. et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg. Med. Chem. Lett. 11, 2775–2778 (2001). · doi:10.1016/s0960-894x(01)00571-6
  5. Wilhelm, S. et al. BAY 43-9006, a novel Raf-1 kinase inhibitor (RKI) blocks the Raf/MEK/ERK pathway in tumor cells. Proc. Am. Assoc. Cancer Res. 42, 923 (2001).
  6. Chang, Y. S. et al. BAY 43-9006 (Sorafenib) inhibits ectopic and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis. Clin. Cancer Res. 46, 5831 (2005).
  7. Liu, L. et al. Sorafenib (BAY 43-9006) inhibits the Raf/MEK/ERK pathway in hepatocellular carcinoma (HCC) cells and produces robust efficacy against PLC/PRF/5 HCC tumors in mice. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
  8. Kupsch, P. et al. Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer 5, 188–196 (2005). · doi:10.3816/ccc.2005.n.030
  9. Flaherty, K. T. et al. Sorafenib combined with carboplatin and paclitaxel for metastatic melanoma: PFS and response versus B-Raf status. Proc. 4th Intl. Symp. Targeted Anticancer Ther. Amsterdam, The Netherlands [online] , (2006).
  10. Awada, A. et al. A Phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with Taxotere in patients with advanced solid tumors. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Geneva, Switzerland (2004).
  11. Steinbild, S. et al. Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors. J. Clin. Oncol. 23, 3115 (2005). · doi:10.1200/jco.2005.23.16_suppl.3115
  12. Eisen, T. et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J. Clin. Oncol. 23, 7508 (2005). · doi:10.1200/jco.2005.23.16_suppl.7508
  13. Gollob, J. et al. Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma. Eur. J. Cancer Supplements 3, 226 (2005).
  14. Robert, C. et al. Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma. Eur. J. Cancer Supplements 3, 254 (2005).
  15. Escudier, B. et al. Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur. J. Cancer Supplements 3, 226 (2005). Pivotal Phase III trial confirming sorafenib's significant PFS benefit and acceptable tolerability in patients with advanced refractory RCC. These findings formed the basis of sorafenib's recent FDA approval for this indication.
  16. Abou-Alfa, G. K. et al. Phase II biomarker analysis of sorafenib (BAY 43-9006) in patients with advanced hepatocellular carcinoma. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
  17. Gatzemeier, U. et al. Phase II trial of single-agent sorafenib in patients with advanced non-small-cell lung carcinoma. J. Clin. Oncol. 24, 364s (2006). · doi:10.1200/jco.2006.24.18_suppl.7002
  18. Steinbild, S. et al. Phase II study of sorafenib (BAY43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research — EWIV (CESAR). J. Clin. Oncol. 24, 144s (2006). · doi:10.1200/jco.2006.24.18_suppl.3094
  19. Dahut, W. L. et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J. Clin. Oncol. 24, 218s (2006). · doi:10.1200/jco.2006.24.18_suppl.4506
  20. Moreno-Aspitia, A. et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J. Clin. Oncol. 24, 577 (2006). · doi:10.1200/jco.2006.24.18_suppl.577
  21. Lorigan, P. et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J. Clin. Oncol. 24, 8012 (2006). · doi:10.1200/jco.2006.24.18_suppl.8012
  22. Sosman, J. et al. A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). J. Clin. Oncol. 24, 128s (2006). · doi:10.1200/jco.2006.24.18_suppl.3031
  23. Elting, J. et al. Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma. Proc. Am. Assoc. Cancer Res. 47, A2909 (2006).
  24. Advani, A. S. C-kit as a target in the treatment of acute myelogenous leukemia. Curr. Hematol. Rep. 4, 51–58 (2005).
  25. Chen, L. L. et al. Imatinib resistance in gastrointestinal stromal tumors. Curr. Oncol. Rep. 7, 293–299 (2005). · doi:10.1007/s11912-005-0053-6
  26. Blumenschein, G. R. et al. Phase II multicenter uncontrolled trial of single agent sorafenib (BAY 43-9006) in relapsed or refractory advanced non-small cell lung cancer. Poster presentation Am. Assoc. Cancer Res.–Natl Cancer Inst.–Eur. Organiz. Res. Treat. Cancer. Philadelphia, Pennsylvania (2005).
  27. Levy, J. et al. Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006). Proc. Am. Assoc. Cancer Res. 47, 213–214 (2006).

Cited by

See all 1,829

Metadata

Authors
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. A., Schwartz, B., Simantov, R., & Kelley, S.
Venue
Nature Reviews Drug Discovery
Published
2006-10-01
Volume
5
Issue
10
Pages
835-844
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2061345986
Cited by
1,829
References
69
FWCI
9.96
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.